Similarly, the blood cultures (liquid biopsy), serum/plasma, tissue samples (solid biopsy) and SAF (non-invasive) of patients with diabetes and/or cancer can be investigated for potentially risen levels of MG and other glycation adducts to monitor the disease stage and target treatment accordingly with AGE-RAGE inhibitors/antagonists in combination with conventional chemotherapy, providing prognostic values and potentiality of reverting or preventing cancer progression, metastasis and chemo-resistance. The gene discussed is RENBP; the disease is diabetes mellitus.